Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Carcinoma, Non-Small-Cell Lung 111Lung Neoplasms 54Hodgkin Disease 22Neoplasm Metastasis 17Recurrence 15Lymphoma 15Triple Negative Breast Neoplasms 14Neoplasms 14Prostatic Neoplasms 10Adenocarcinoma of Lung 10Sarcoma 9Rhabdomyosarcoma 9Uterine Cervical Neoplasms 8Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 6Small Cell Lung Carcinoma 5Ovarian Neoplasms 5Mesothelioma, Malignant 5Breast Neoplasms, Male 5Brain Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4NSCLC 4Multiple Myeloma 4Unspecified Adult Solid Tumor, Protocol Specific 3Mesothelioma 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Breast Cancer × Vinorelbine × Clear all
NCT03270007 2020-10-28

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

Peking University

Phase 4 Unknown
304 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡